keyword
MENU ▼
Read by QxMD icon Read
search

HPV vaccines safety

keyword
https://www.readbyqxmd.com/read/29211620/safety-profile-of-the-9-valent-human-papillomavirus-vaccine-assessment-in-prior-quadrivalent-hpv-vaccine-recipients-and-in-men-16-to-26%C3%A2-years-of-age
#1
E D Moreira, A R Giuliano, J de Hoon, O-E Iversen, E A Joura, J Restrepo, P Van Damme, C Vandermeulen, M C Ellison, A Krick, C Shields, B Heiles, A Luxembourg
A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls and women 16-26 years of age, showed that the 9vHPV vaccine was generally well tolerated. Additional safety analyses were conducted to include the results of new clinical studies. The safety profile of the 9vHPV vaccine in prior qHPV vaccine recipients (n=3756 from 1 randomized controlled trial and 2 open-label extension studies) and young men (n=248 9vHPV and n=248 qHPV vaccine recipients from 1 randomized controlled trial) was evaluated...
December 6, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29179869/overcoming-barriers-in-hpv-vaccination-and-screening-programs
#2
Alex Vorsters, Marc Arbyn, Marc Baay, Xavier Bosch, Silvia de Sanjosé, Sharon Hanley, Emilie Karafillakis, Pier Luigi Lopalco, Kevin G Pollock, Joanne Yarwood, Pierre Van Damme
The Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs. Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring. Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine...
December 2017: Papillomavirus Research
https://www.readbyqxmd.com/read/29174109/comparative-immunogenicity-and-safety-of-human-papillomavirus-hpv-16-18-as04-adjuvanted-vaccine-and-4vhpv-vaccine-administered-according-to-two-or-three-dose-schedules-in-girls-aged-9-14%C3%A2-years-results-to-month-36-from-a-randomized-trial
#3
Ting Fan Leung, Anthony Pak-Yin Liu, Fong Seng Lim, Franck Thollot, Helen May Lin Oh, Bee Wah Lee, Lars Rombo, Ngiap Chuan Tan, Roman Rouzier, Stéphanie De Simoni, Pemmaraju Suryakiran, Marjan Hezareh, Florence Thomas, Nicolas Folschweiller, Frank Struyf
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of two doses (2D) of the HPV-16/18 AS04-adjuvanted vaccine (2D of AS04-HPV-16/18) vs. two or three doses of the 4vHPV vaccine [2D or 3D of 4vHPV] in 1075 healthy girls aged 9-14 years. Girls were randomized (1:1:1) to receive 2D of AS04-HPV-16/18 at months (M) 0, 6 (N = 359), 2D of 4vHPV at M0, 6 (N = 358) or 3D of 4vHPV at M0, 2, 6 (N = 358). 351, 339 and 346 girls, respectively, returned for the concluding visit at M36...
November 23, 2017: Vaccine
https://www.readbyqxmd.com/read/29161198/a-systematic-review-of-factors-influencing-human-papillomavirus-vaccination-among-immigrant-parents-in-the-united-states
#4
Kyounghae Kim, Anna-Rae LeClaire
To critically appraise factors influencing human papillomavirus (HPV) vaccination among immigrant parents in the United States, a comprehensive search of electronic databases and reference lists was conducted. The findings from 22 articles were ordered based on a socio-ecological model. About 30% of children initiated and 14% completed a 3-dose series. Correlates of HPV vaccine initiation rates included lack of information, concerns about vaccine safety and promiscuity, providers' recommendations, school mandates, financial issues, immigration laws, and living in disadvantaged neighborhoods...
November 21, 2017: Health Care for Women International
https://www.readbyqxmd.com/read/29157955/development-of-a-goat-model-for-evaluation-of-withaferin-a-cervical-implants-for-the-treatment-of-cervical-intraepithelial-neoplasia
#5
Leslie C Sherwood, Farrukh Aqil, Manicka V Vadhanam, Jeyaprakash Jeyabalan, Radha Munagala, David Hoetker, Sanjay Srivastava, Inder P Singh, Scott Cambron, Martin O'Toole, Wendy Spencer, Lynn P Parker, Ramesh C Gupta
Cervical cancer is caused by human papillomavirus (HPV). The disease develops over many years through a series of precancerous lesions. Cervical cancer can be prevented by HPV-vaccination, screening and treatment of precancer before development of cervical cancer. The treatment of high-grade cervical dysplasia (CIN(2+)) has traditionally been by cervical conization. Surgical procedures are associated with increased risk of undesirable side effects including bleeding, infection, scarring (stenosis), infertility and complications in later pregnancies...
November 17, 2017: Experimental and Molecular Pathology
https://www.readbyqxmd.com/read/29098504/examining-hpv-and-hpv-vaccine-related-cognitions-and-acceptability-among-us-born-and-immigrant-hispanics-and-us-born-and-immigrant-non-hispanic-blacks-a-preliminary-catchment-area-study
#6
Kimlin Tam Ashing, Agatha Carrington, Camille Ragin, Veronica Roach
PURPOSE: Disparities in HPV vaccination exist. Therefore, we investigated the distinction and disparities in HPV- and HPV vaccine-related cognitions and acceptability among US-born African Americans (AA) and Black immigrants, and between US-born Latinas and Latina immigrants. METHODS: Secondary data analyses were conducted with 383 female adults divided into non-Hispanic Blacks-(1) AA born in the US (n = 129) and (2) Black immigrants (n = 53), and Hispanics-(3) Latinas born in the US (n = 57) and (4) Latina immigrants (n = 144)...
November 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/29080142/correction-to-safety-concerns-with-hpv-vaccines-continue-to-linger-are-current-vaccine-pharmacovigilance-practices-sufficient
#7
Rebecca E Chandler
The following disclaimer was missing from the article.
October 28, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29074192/ipvs-policy-statement-on-safety-of-hpv-vaccines
#8
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Papillomavirus Research
https://www.readbyqxmd.com/read/29061232/reports-of-postural-orthostatic-tachycardia-syndrome-after-human-papillomavirus-vaccination-in-the-vaccine-adverse-event-reporting-system
#9
Jorge Arana, Adamma Mba-Jonas, Christopher Jankosky, Paige Lewis, Pedro L Moro, Tom T Shimabukuro, Maria Cano
PURPOSE: Human papillomavirus (HPV) vaccination prevents infections with HPV strains that cause certain cancers. Reports of postural orthostatic tachycardia syndrome (POTS) following HPV vaccination have raised safety concerns. We reviewed POTS reports submitted to the Vaccine Adverse Event Reporting System (VAERS). METHODS: We searched the VAERS database for reports of POTS following any type of HPV vaccination (bivalent, quadrivalent, or nonavalent) from June 2006 to August 2015...
November 2017: Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine
https://www.readbyqxmd.com/read/29044769/human-papillomavirus-vaccination-of-adult-women-and-risk-of-autoimmune-and-neurological-diseases
#10
A Hviid, H Svanström, N M Scheller, O Grönlund, B Pasternak, L Arnheim-Dahlström
BACKGROUND: Since 2006, human papillomavirus (HPV) vaccines have been introduced in many countries worldwide. Whilst safety studies have been reassuring, focus has been on the primary target group, the young adolescent girls. However, it is also important to evaluate safety in adult women where background disease rates and safety issues could differ significantly. OBJECTIVE: We took advantage of the unique Danish and Swedish nationwide healthcare registers to conduct a cohort study comparing incidence rate ratios (RRs) of 45 preselected serious chronic diseases in quadrivalent HPV (qHPV)-vaccinated and qHPV-unvaccinated adult women 18-44 years of age...
October 18, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28986659/hpv-vaccination-in-japan-results-of-a-3-year-follow-up-survey-of-obstetricians-and-gynecologists-regarding-their-opinions-toward-the-vaccine
#11
Masaaki Sawada, Yutaka Ueda, Asami Yagi, Akiko Morimoto, Ruriko Nakae, Reisa Kakubari, Hazuki Abe, Tomomi Egawa-Takata, Tadashi Iwamiya, Shinya Matsuzaki, Eiji Kobayashi, Kiyoshi Yoshino, Tadashi Kimura
BACKGROUND: In Japan, the cervical cancer preventative HPV vaccination rate has dramatically declined, directly as a result of repeated broadcasts of so-called adverse events and the resulting suspension of the government's recommendation. Our previous survey of obstetricians and gynecologists in Japan regarding their opinions toward HPV vaccination revealed that these key specialists were as negatively influenced by the reports of purported negative events as were the general population...
October 6, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28986092/population-based-hpv-vaccination-programmes-are-safe-and-effective-2017-update-and-the-impetus-for-achieving-better-global-coverage
#12
REVIEW
Julia M L Brotherton, Paul N Bloem
Persistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that prophylactic HPV vaccines are immunogenic and effective against targeted-type HPV infections and type-specific genital lesions, including high-grade cervical intraepithelial neoplasia (CIN), when administered prior to HPV infection. There is good evidence that HPV vaccines are safe in population usage, with the most frequent adverse event being injection-site reactions...
September 6, 2017: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28984053/ten-year-immune-persistence-and-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-females-vaccinated-at-15-55%C3%A2-years-of-age
#13
Tino F Schwarz, Andrzej Galaj, Marek Spaczynski, Jacek Wysocki, Andreas M Kaufmann, Sylviane Poncelet, Pemmaraju V Suryakiran, Nicolas Folschweiller, Florence Thomas, Lan Lin, Frank Struyf
Women remain at risk of human papillomavirus (HPV) infection for most of their lives. The duration of protection against HPV-16/18 from prophylactic vaccination remains unknown. We investigated the 10-year immune response and long-term safety profile of the HPV-16/18 AS04-adjuvanted vaccine (AS04-HPV-16/18 vaccine) in females aged between 15 and 55 years at first vaccination. Females who received primary vaccination with three doses of AS04-HPV-16/18 vaccine in the primary phase-III study (NCT00196937) were invited to attend annual evaluations for long-term immunogenicity and safety...
November 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28970457/pharmacists-attitudes-and-perceived-barriers-to-human-papillomavirus-hpv-vaccination-services
#14
Tessa J Hastings, Lindsey A Hohmann, Stuart J McFarland, Benjamin S Teeter, Salisa C Westrick
Use of non-traditional settings such as community pharmacies has been suggested to increase human papillomavirus (HPV) vaccination uptake and completion rates. The objectives of this study were to explore HPV vaccination services and strategies employed by pharmacies to increase HPV vaccine uptake, pharmacists' attitudes towards the HPV vaccine, and pharmacists' perceived barriers to providing HPV vaccination services in community pharmacies. A pre-piloted mail survey was sent to 350 randomly selected community pharmacies in Alabama in 2014...
August 7, 2017: Pharmacy (Basel, Switzerland)
https://www.readbyqxmd.com/read/28969653/association-between-parent-attitudes-and-receipt-of-human-papillomavirus-vaccine-in-adolescents
#15
Jeffrey J VanWormer, Casper G Bendixsen, Elizabeth R Vickers, Shannon Stokley, Michael M McNeil, Julianne Gee, Edward A Belongia, Huong Q McLean
BACKGROUND: Human papillomavirus (HPV) vaccine coverage rates remain low. This is believed to reflect parental hesitancy, but few studies have examined how changes in parents' attitudes impact HPV vaccine uptake. This study examined the association between changes in parents' vaccine attitudes and HPV vaccine receipt in their adolescent children. METHODS: A baseline and 1-year follow-up survey of HPV vaccine attitudes was administered to parents of 11-17 year olds who had not completed the HPV vaccine series...
October 2, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28950675/cervical-cancer-prevention-through-hpv-vaccination-in-low-and-middle-income-countries-in-asia
#16
Zheng Quan Toh, Paul V Licciardi, Fiona M Russell, Suzanne M Garland, Tsetsegsaikhan Batmunkh, Edward K Mulholland
Cervical cancer is ranked the first or second most common cancer in women of low- and middle-income countries (LMICs) in Asia. Cervical cancer is almost exclusively caused by human papillomavirus (HPV), and majority of the cases can be prevented with the use of HPV vaccines. The HPV vaccines have demonstrated high vaccine efficacies against HPV infection and cervical cancer precursors in clinical and post-marketing studies, and are in use in most high-income countries. However, their use in LMICs are limited mainly due to the high costs and logistics in delivering multiple doses of the vaccine...
September 27, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28935469/risk-of-guillain-barr%C3%A3-syndrome-following-quadrivalent-human-papillomavirus-vaccine-in-the-vaccine-safety-datalink
#17
Julianne Gee, Lakshmi Sukumaran, Eric Weintraub
OBJECTIVE: Describe the Vaccine Safety Datalink's (VSD) Guillain Barré Syndrome (GBS) surveillance following quadrivalent HPV vaccine (4vHPV) from 2006 through 2015. METHODS: Among 4vHPV vaccinated persons aged 9-26, ICD-9 coded GBS was identified in VSD's electronic data. Medical records were reviewed and adjudicated to confirm GBS. We calculated incidence rates of confirmed GBS within 1-42days following 4vHPV with a one-sided 95% confidence interval. RESULTS: Following 2,773,185 4vHPV doses, we confirmed 1 case of GBS in a male and no cases among females...
October 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28933635/factors-involved-in-human-papillomavirus-hpv-vaccine-hesitancy-among-women-in-the-south-east-asian-region-sear-and-western-pacific-region-wpr-a-scoping-review
#18
Diviya Santhanes, Che Pui Wong, Yan Ye Yap, Saw Pui San, Nathorn Chaiyakunapruk, Tahir Mehmood Khan
A scoping review was performed to identify factors that may lead to human papillomavirus (HPV) vaccine hesitancy among women in low- and middle-income countries in South East Asian Region (SEAR) and Western Pacific Region (WPR). A systematic search of English and non-English articles using Pubmed, EMBASE, PsycINFO, Cochrane, MEDLINE, and CINAHL plus was conducted. Only 63 studies conducted in SEAR and WPR were included from inception until December 2016. Results of these studies have shown that poor awareness and knowledge of practices on cervical cancer prevention was evident in both SEAR and WPR...
September 21, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28886907/final-efficacy-immunogenicity-and-safety-analyses-of-a-nine-valent-human-papillomavirus-vaccine-in-women-aged-16-26-years-a-randomised-double-blind-trial
#19
Warner K Huh, Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A Ault, Deborah Bartholomew, Ramon M Cestero, Edison N Fedrizzi, Angelica L Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T Stapleton, Dorothy J Wiley, Alex Ferenczy, Robert Kurman, Brigitte M Ronnett, Mark H Stoler, Jack Cuzick, Suzanne M Garland, Susanne K Kjaer, Oliver M Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C Roberts, Christine Shields, Alain Luxembourg
BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. We aimed to report efficacy of the 9vHPV vaccine for up to 6 years following first administration and antibody responses over 5 years...
November 11, 2017: Lancet
https://www.readbyqxmd.com/read/28875439/current-status-and-future-prospects-for-human-papillomavirus-vaccines
#20
REVIEW
Hyoung Jin Kim, Hong-Jin Kim
Cervical cancer is the fourth most frequent cancer among women worldwide. Human papillomaviruses (HPVs) cause almost all cervical cancers in low-income countries. Three prophylactic HPV virus-like particle-based vaccines have been licensed to date, and they have all shown high efficacy and reliable safety profiles. However, isolated safety issues have resulted in a reluctance to use these vaccinations. In addition, the high prices of the vaccinations have caused the inequitable distribution of the vaccine: the prices are unaffordable for low-income countries...
September 2017: Archives of Pharmacal Research
keyword
keyword
102610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"